BC Week In Review | Aug 3, 2015
Company News

Zhejiang Wansheng Pharmaceutical, 3SBio deal

3SBio will acquire Zhejiang Wansheng for RMB528 million ($85.1 million) in cash. Zhejiang Wansheng markets cancer, diabetes and hypertension products in China and had net sales of RMB279.4 million ($45 million) in 2014. 3SBio, which...
BC Extra | Jul 25, 2015
Company News

3SBio acquires Zhejiang Wansheng

3SBio Inc. (HKSE:1530) will acquire Zhejiang Wansheng Pharmaceutical Co. Ltd. (Hangzhou, China) for RMB528 million ($85.1 million). Zhejiang Wansheng markets oncology, diabetes and hypertension products. 3SBio said the acquisition would allow the company to expand...
BC Extra | Jun 11, 2015
Financial News

3SBio raises HK$4.4B in Hong Kong IPO

3SBio Inc. (HKSE:1530) raised HK$4.4 billion ($569.2 million) through the sale of 484.9 million shares at HK$9.10 in an IPO on the Hong Kong Stock Exchange. The price values the company at HK$22.1 billion ($2.8...
BioCentury | Mar 30, 2015
Regulation

China gears up for biosimilars

Multinational biosimilars companies that lack manufacturing facilities in China could find themselves at a disadvantage to local rivals in getting biosimilars approved. China FDA clarified in a recently released guideline that while biosimilars will be...
BioCentury | Mar 2, 2015
Finance

China's 3SBio plans 2nd IPO

China's 3SBio Inc. is taking itself public again, filing for an IPO on the Hong Kong Stock Exchange to fund both expansion on the mainland and to build on its beachhead in Europe. While the...
BC Extra | Feb 24, 2015
Financial News

China's 3SBio aims to go public again

3SBio Inc. (Shenyang, China) proposed an IPO on the Hong Kong Stock Exchange. Morgan Stanley; Goldman Sachs; and CITIC Securities International are underwriters. 3SBio was traded on NASDAQ from 2007 until 2013, when Chairman and...
BioCentury | Mar 18, 2013
Product Development

Bettering China's biosimilars

While many homegrown biologics marketed in China could be perceived as biosimilars, most are unlikely to meet international standards and are not marketed as such in China. But with an uptick in returnees and VC...
BC Week In Review | Feb 11, 2013
Company News

3SBio deal

3SBio said its board approved a proposal to go private from CEO and Chairman Jing Lou and CPEChina Fund L.P. for $2.20 per share in cash, or $15.40 per ADS. The price values 3SBio at...
BC Week In Review | Oct 8, 2012
Company News

3SBio hematology, biosimilars news

3SBio's special committee of independent directors hired Jefferies as a financial advisor to review and evaluate a non-binding proposal to go private from CEO and Chairman Jing Lou and CPEChina Fund L.P. BofA Merrill Lynch...
BC Week In Review | Sep 17, 2012
Company News

3SBio deal

3SBio said it is evaluating a non-binding proposal from CEO and Chairman Jing Lou and CPEChina Fund L.P. to acquire the Chinese biotech for $15 per ADS in cash. The price values 3SBio at about...
Items per page:
1 - 10 of 21